Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP4K4_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP4K4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MAP4K4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAP4K4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP4K4_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAP4K4_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/MAP4K4_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00901308 | Lung | IAC | tissue migration | 66/2061 | 365/18723 | 3.32e-05 | 8.30e-04 | 66 |
GO:00465784 | Lung | IAC | regulation of Ras protein signal transduction | 40/2061 | 189/18723 | 3.50e-05 | 8.65e-04 | 40 |
GO:00106328 | Lung | IAC | regulation of epithelial cell migration | 55/2061 | 292/18723 | 4.68e-05 | 1.08e-03 | 55 |
GO:00108118 | Lung | IAC | positive regulation of cell-substrate adhesion | 29/2061 | 123/18723 | 5.35e-05 | 1.21e-03 | 29 |
GO:00016677 | Lung | IAC | ameboidal-type cell migration | 80/2061 | 475/18723 | 6.90e-05 | 1.47e-03 | 80 |
GO:00435475 | Lung | IAC | positive regulation of GTPase activity | 48/2061 | 255/18723 | 1.40e-04 | 2.60e-03 | 48 |
GO:00106347 | Lung | IAC | positive regulation of epithelial cell migration | 36/2061 | 176/18723 | 1.73e-04 | 3.07e-03 | 36 |
GO:00019546 | Lung | IAC | positive regulation of cell-matrix adhesion | 16/2061 | 58/18723 | 3.85e-04 | 5.87e-03 | 16 |
GO:00097438 | Lung | IAC | response to carbohydrate | 46/2061 | 253/18723 | 4.28e-04 | 6.37e-03 | 46 |
GO:00518943 | Lung | IAC | positive regulation of focal adhesion assembly | 10/2061 | 28/18723 | 5.17e-04 | 7.37e-03 | 10 |
GO:0032011 | Lung | IAC | ARF protein signal transduction | 8/2061 | 19/18723 | 5.25e-04 | 7.44e-03 | 8 |
GO:0032012 | Lung | IAC | regulation of ARF protein signal transduction | 8/2061 | 19/18723 | 5.25e-04 | 7.44e-03 | 8 |
GO:00109774 | Lung | IAC | negative regulation of neuron projection development | 27/2061 | 137/18723 | 1.88e-03 | 1.92e-02 | 27 |
GO:01501173 | Lung | IAC | positive regulation of cell-substrate junction organization | 10/2061 | 33/18723 | 2.18e-03 | 2.15e-02 | 10 |
GO:00342848 | Lung | IAC | response to monosaccharide | 39/2061 | 225/18723 | 2.75e-03 | 2.51e-02 | 39 |
GO:00224118 | Lung | IAC | cellular component disassembly | 68/2061 | 443/18723 | 2.89e-03 | 2.60e-02 | 68 |
GO:00310994 | Lung | IAC | regeneration | 34/2061 | 198/18723 | 5.73e-03 | 4.18e-02 | 34 |
GO:0010812 | Lung | IAC | negative regulation of cell-substrate adhesion | 15/2061 | 68/18723 | 6.28e-03 | 4.49e-02 | 15 |
GO:000716012 | Lung | AIS | cell-matrix adhesion | 60/1849 | 233/18723 | 2.19e-12 | 2.55e-09 | 60 |
GO:003158913 | Lung | AIS | cell-substrate adhesion | 80/1849 | 363/18723 | 3.80e-12 | 3.16e-09 | 80 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP4K4 | SNV | Missense_Mutation | | c.3526N>T | p.Val1176Phe | p.V1176F | | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.98) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.3715N>C | p.Phe1239Leu | p.F1239L | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.931) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAP4K4 | SNV | Missense_Mutation | | c.451N>T | p.His151Tyr | p.H151Y | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.957) | TCGA-AC-A2FG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR |
MAP4K4 | SNV | Missense_Mutation | novel | c.643N>A | p.Asp215Asn | p.D215N | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.994) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.1246G>C | p.Glu416Gln | p.E416Q | | protein_coding | tolerated_low_confidence(0.09) | possibly_damaging(0.888) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP4K4 | SNV | Missense_Mutation | | c.592N>A | p.Glu198Lys | p.E198K | | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAP4K4 | SNV | Missense_Mutation | | c.673N>C | p.Glu225Gln | p.E225Q | | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.991) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAP4K4 | SNV | Missense_Mutation | | c.2322N>C | p.Leu774Phe | p.L774F | | protein_coding | tolerated_low_confidence(0.59) | probably_damaging(0.991) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MAP4K4 | SNV | Missense_Mutation | novel | c.2741N>C | p.Gly914Ala | p.G914A | | protein_coding | tolerated_low_confidence(0.39) | probably_damaging(0.997) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
MAP4K4 | insertion | Nonsense_Mutation | novel | c.1598_1599insGGAGGGTCAGACATAGACACAAGAGACGTAGAT | p.Asp533delinsGluGluGlyGlnThrTerThrGlnGluThrTerIle | p.D533delinsEEGQT*TQET*I | | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | CYC-116 | CYC-116 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SOTRASTAURIN | SOTRASTAURIN | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | PAZOPANIB | PAZOPANIB | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | DNDI1417467 | CHEMBL1997335 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | AST-487 | AST-487 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | PD-0166285 | PD-0166285 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | SB-220025 | SB-220025 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | CEDIRANIB | CEDIRANIB | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | OSI-632 | OSI-632 | |
9448 | MAP4K4 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME | | AZD-1152-HQPA | AZD-1152-HQPA | |